Irritable bowel syndrome
Therapeutic area
Gastroenterology
Rare disease
No
- Definition
- Irritable bowel syndrome (IBS) is a chronic functional condition of the lower gastrointestinal (GI) tract characterized by abdominal pain or discomfort and disordered bowel habit (diarrhea, constipation, or fluctuation between the two).
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Irritable bowel syndrome
- Therapeutic area
- Gastroenterology
- irritable bowel syndrome
- IBS
- irritable bowel syndrome
- irritable colon
- mucus colitis
- spastic colon
- Disease mechanisms
- Syndromic
- All therapeutic areas
- Gastroenterology
- Severity
- Mild
- MONDO ID
- MONDO:0005052
- Parent condition
- MONDO:0002254
Related records
Broader conditions (6)
- Digestive system disorder
- Disease
- Disease by body system or component
- Human disease
- Intestinal disorder
- Syndromic disease
Trials (1,008)
- "Efficacy and Safety of Linaclotide in Chronic Constipation"
- "Functional Bowel Disorder. Investigation in General Practice"
- (FODMAP) Diet on Improving Symptoms of Patients With Irritable Bowel Syndrome
- 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
- 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
- 1H-19F Gastrointestinal MRI in Health and IBS
- 24 Hrs Histamine Profile in Healthy Persons and Patients With Food Intolerance
- 25-hydroxyvitamin D and Fatigue: The VITALITY Study
- 52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
- 8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS
- A 14-week Pilot Prospective Clinical Trial With BiOkuris Product in Patients With Irritable Bowel Syndrome
- A Clinical Study to Determine the Safety and Efficacy of An Oral Probiotic Supplementation in the Management of Irritable Bowel Syndrome With Protein Digestion.
- A Clinical Trial Evaluating Diets for IBS
- A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)
- A Comparison of Three Different Treatment Options for Irritable Bowel Syndrome
- A Computer-Based Intervention for Medically Unexplained Physical Symptoms
- A Cross-sectional Study on IBS Subtypes, Chinese Medicine Pattern and Host-gut Microbiota Metabolic Interactions
- A Flexible Clinical Trial to Test if Freeze-dried Fecal Microbiota Therapy Helps Treat Diarrhea-predominant Irritable Bowel Syndrome or Prevent Recurring C. Difficile Infections.
- A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)
- A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically
Approved drugs (8)
- Alosetron hydrochloride
- Clindamycin phosphate
- Dicyclomine hydrochloride
- Eluxadoline
- Linaclotide
- Lubiprostone
- Tegaserod maleate
- Tenapanor hydrochloride
Drugs in development (80)
- Acetylcysteine Phase 1
- Alosetron Phase 3
- Anise oil Phase 3
- Asimadoline Phase 3
- Bifidobacterium SPP. Phase 3
- BOS-589 Phase 2
- Charcoal, activated Phase 2
- Chenodiol Phase 2
- Cholecalciferol Phase 1
- Cilansetron Phase 3
- Citalopram Phase 2
- Crofelemer Phase 2
- DA-6886 Phase 1
- DDP-225 Phase 2
- Dexloxiglumide Phase 3
- Dextofisopam Phase 2
- Dextromethorphan Phase 2
- DNK333 Phase 2
- Doxepin Phase 2
- Dronabinol Phase 2
Other linked drugs (11)
- Amitriptyline
- Clidinium
- Desipramine
- Drotaverine
- Esketamine
- Methantheline
- Ornidazole
- Oxitriptan
- Prifinium
- Sulfasalazine
- Tegaserod